-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BBP-398 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BBP-398 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BBP-398 in Colorectal Cancer Drug Details: BBP-398 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BBP-398 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BBP-398 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BBP-398 in Pancreatic Ductal Adenocarcinoma Drug Details: BBP-398 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BBP-398 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BBP-398 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BBP-398 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: BBP-398 is...
-
Product Insights
NewNet Present Value Model: BridgeBio Pharma Inc’s BBP-631
Empower your strategies with our Net Present Value Model: BridgeBio Pharma Inc's BBP-631 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acoramidis Hydrochloride in Familial Amyloid Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acoramidis Hydrochloride in Familial Amyloid Cardiomyopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acoramidis Hydrochloride in Familial Amyloid Cardiomyopathy Drug Details: BBP-265 (AG-10)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BBP-671 in Propionic Acidemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BBP-671 in Propionic AcidemiaDrug Details:BBP-671 is under development for the treatment of pantothenate kinase-associated neurodegeneration, organic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BBP-711 in Primary Hyperoxaluria Type I
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BBP-711 in Primary Hyperoxaluria Type I report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BDB-001 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BDB-001 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BDB-001 in Non-Small Cell Lung Cancer Drug Details: BDB-001...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATX-101 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATX-101 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATX-101 in Non-Small Cell Lung Cancer Drug Details: ATX-101...